TLX
$8.75+0.18 (+2.10%)
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
Recent News
Telix Advances Radiopharma Platform With Key Trials And US Manufacturing Shift
Telix Pharmaceuticals (ASX:TLX) has resubmitted its NDA for TLX101-Px, a PET imaging agent for brain cancer. The company reported that Part 1 of the global Phase 3 ProstACT study for TLX591-Tx in prostate cancer met primary safety and tolerability objectives. Telix expanded its U.S. manufacturing footprint with new cyclotron installations to support in-house radioisotope production and supply resilience. At a share price of A$12.75, Telix Pharmaceuticals (ASX:TLX) sits against a mixed...
What Powers BWXT's Strength in Nuclear Medicine Manufacturing?
BWX Technologies expands beyond defense, boosting nuclear medicine with isotopes, new capabilities and a growing role in cancer diagnostics and treatment.
Talanx Q4 Earnings Call Highlights
Talanx (ETR:TLX) management highlighted a record 2025, pointing to higher earnings, a stronger balance sheet and a sharply increased dividend, while cautioning that unusually low catastrophe losses helped results and should normalize in 2026. Record earnings and a higher dividend CEO Torsten Leue s
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday as Investors Weigh Middle East War Signals, Oil Price Volatility
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.3% and the actively tr
Telix’s AI Imaging Moves And Glioma Filing Contrast With Valuation Discount
Telix Pharmaceuticals (ASX:TLX) announced a collaboration with University Hospital Essen to develop AI based prognostic models using PSMA PET imaging in prostate cancer. The company has also submitted a marketing authorization application in Europe for TLX101 Px, its glioma imaging candidate. Both updates relate to Telix's nuclear medicine pipeline and were reported ahead of routine earnings or guidance updates. Telix focuses on radiopharmaceuticals for cancer care, and these announcements...